Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer

BACKGROUND: The efficacy and safety of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 in combination with pemetrexed and cisplatin was evaluated in patients with advanced non-squamous non–small-cell lung cancer (NSCLC). METHOD...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Belani, Chandra P, Yamamoto, Nobuyuki, Bondarenko, Igor M, Poltoratskiy, Artem, Novello, Silvia, Tang, Jie, Bycott, Paul, Niethammer, Andreas G, Ingrosso, Antonella, Kim, Sinil, Scagliotti, Giorgio V
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2014
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4017965/
https://ncbi.nlm.nih.gov/pubmed/24766732
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-290
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller